Summary：Datasea Breakthrough: FDA Registration Advances for Revolutionary Brain-Computer Interface Technolog

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

Datasea Breakthrough: FDA Registration Advances for Revolutionary Brain-Computer Interface Technology

BEIJING, June 12, 2026 /PRNewswire/ -- Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in the research, development, and commercialization of innovative acoustic and brain-computer interface ("BCI") technologies, has made significant strides in advancing its preparatory work for the internationalization of its product portfolio. The Company's latest development involves the progression of its BCI technology towards FDA registration, a critical step towards entering the U.S. market.

Key Developments
The Company's BCI technology, which enables seamless communication between the human brain and digital devices, has garnered significant attention globally due to its potential to revolutionize the treatment of neurological disorders and enhance human cognition. Datasea's advancements in FDA registration underscore its commitment to ensuring the highest standards of safety and efficacy for its products. The Company's proactive approach to regulatory compliance is expected to facilitate a smoother entry into the U.S. market, a significant milestone in its global expansion strategy.

Industry Analysis
The BCI market is poised for substantial growth, driven by increasing demand for innovative treatments for neurological conditions and advancements in technology. Datasea's progress in FDA registration positions the Company at the forefront of this burgeoning market. Analysts predict that the global BCI market will witness significant expansion in the coming years, with applications extending beyond medical treatment to include gaming, education, and other industries. Datasea's early mover advantage and commitment to innovation are likely to yield substantial benefits as the market continues to evolve.

Future Outlook
As Datasea continues to advance its BCI technology through the FDA registration process, the Company is well-positioned to capitalize on emerging opportunities in the global market. With a robust product pipeline and a strong focus on research and development, Datasea is poised to make a meaningful impact in the BCI industry. The Company's progress is expected to drive growth and create new opportunities for stakeholders, including investors, customers, and partners.

Conclusion
Datasea's breakthrough in advancing its BCI technology towards FDA registration marks a significant milestone in the Company's journey towards internationalization. With a strong foundation in innovation and a commitment to regulatory compliance, Datasea is well-positioned to capitalize on the growing demand for BCI technology. As the Company continues to push the boundaries of what is possible in the field of brain-computer interfaces, investors and industry observers alike will be watching closely for further developments.